Halozyme Therapeutics Inc. (NASDAQ:HALO) finished Wednesday with a subtraction of -$0.68 to close at $42.63, a downside of -1.57 percent. An average of 1,137,600 shares of common stock have been traded in the last five days. There was a fall of -$0.22 in the past week, and it reached a new high 15 times over the past 12 months. The last 20 days have seen an average of 1,231,710 shares traded, while the 50-day average volume stands at 1,114,330.
HALO stock has increased by 14.91% in the last month. The company shares reached their 1-month lowest point of $36.07 on 07/10/23. With the stock rallying to its 52-week high on 01/03/23, shares of the company touched a low of $29.85 and a high of $59.46 in 52 weeks. It has reached a new high 1 time so far this year and lost -25.08% or -$14.27 in price. In spite of this, the price is down -28.30% from the 52-week high.
Insider Transactions
HALO stock investors should be aware that Halozyme Therapeutics Inc. (HALO) stock had its last reported insider trading activity 14 days ago on Jul 27. In this transaction, the insider spent $437,900. PRESIDENT AND CEO, Torley Helen, disposed of 10,000 shares at a price of $42.69 on Jul 26. The insider now owns more than $426,890 worth of shares. Prior to that, PRESIDENT AND CEO Torley Helen went on to Sale 10,000 shares at $42.80 each on Jul 25. An amount of $427,960 was transacted.
Valuation Metrics
Halozyme Therapeutics Inc. (HALO) has a trailing price-to-earnings (P/E) ratio of 32.72. The stock’s beta is 1.24. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 7.90, the price-to-book (PB) ratio at 87.00, and the price-to-cash flow ratio at 21.14.
Financial Health
The quick ratio of Halozyme Therapeutics Inc. for the three months ended June 29 was 5.50, and the current ratio was 6.70, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 22.68 and a total debt to equity ratio of 22.68 for the quarter ending June 29. Halozyme Therapeutics Inc.’s EBITDA margin for the year ending June 29 is 51.37%, while its operating margin for the same period stands at 34.50%. Its gross profit as reported stood at $520.81 million compared to revenue of $660.12 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Halozyme Therapeutics Inc.’s return on assets was 10.10%.
Earnings Surprise
For the three-month period that ended June 29, Halozyme Therapeutics Inc. had $1.5 billion in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of $74.75 million in the quarter, while revenues of $39.62 million were grew 69.65%. The analyst consensus anticipated Halozyme Therapeutics Inc.’s latest quarter earnings to come in at $0.63 per share, but it turned out to be $0.74, a 17.50% surprise. For the quarter, EBITDA amounted to $115.48 million. At the end of the quarter ending June 29, Halozyme Therapeutics Inc.’s stock balance sheet showed total liabilities of 1.66 billion. Shareholders own equity worth $131.92 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Halozyme Therapeutics Inc. (HALO) price momentum. RSI 9-day as of the close on 09 August was 56.87%, suggesting the stock is Neutral, with historical volatility in this time frame at 25.28%.
As of today, HALO’s price is $42.49 -0.51% or -$0.22 from its 5-day moving average. HALO is currently trading +14.63% higher than its 20-day SMA and +18.19% higher than its 100-day SMA. However, the stock’s current price level is +28.40% above the SMA50 and -2.89% below the SMA200.
The stochastic %K and %D were 42.18% and 46.56%, respectively, and the average true range (ATR) was 1.56. With the 14-day stochastic at 34.15% and the average true range at 1.48, the RSI (14) stands at 60.63%. The stock has reached -0.04 on the 9-day MACD Oscillator while the 14-day reading was at -0.20.
Analyst Ratings
H.C. Wainwright launched coverage on Halozyme Therapeutics Inc. (NASDAQ: HALO) in its analyst report released on July 24, 2023. The firm assigned the stock a Buy rating. The consensus rating for Halozyme Therapeutics Inc. (HALO) among analysts is Overweight. According to current brokerage recommendations, 1 brokerage firm advise that investors sell HALO, while 2 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 7 others rate it as a “buy”.
What is HALO’s price target for the next 12 months?
Analysts predict a range of price targets between $26.00 and $72.00, with a median target of $49.00. Taking a look at these predictions, the average price target given by analysts for Halozyme Therapeutics Inc. (HALO) stock is $50.60.
